We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Blended Polymer Reduces Catheter-Related Thrombus

By HospiMedica International staff writers
Posted on 17 Sep 2012
Novel peripherally inserted central catheters (PICCs) have been designed to reduce the accumulation of catheter-related thrombus on and in the catheter.

The AngioDynamics BioFlo PICC is intended for use for an extended period of time for chemotherapy, antibiotic delivery, and other intravascular therapies. More...
It does not contain antibiotics or antimicrobials, agents potentially associated with bacterial resistance. Instead, it is provided with Endexo technology, a permanent and noneluting integral polymer that is blended into the catheter shaft, and thus present throughout the catheter. The resultant passivating surface reduces platelet adhesion, protein adsorption, and thrombus formation. And since it is not superficial or transient (such as in coatings or impregnated materials), Endexo provides long-term durability.

The AngioDynamics BioFlo PICC is also equipped with Pressure Activated Safety Valve (PASV) technology, designed to automatically resist backflow and reduce blood reflux on the inside of the catheter. The valve automatically closes after infusion or upon disconnection, and remains closed during commonly experienced increases in central venous pressure (CVP). In vitro blood loop-model tests have shown that the BioFlo PICC has 87% less thrombus accumulation on its surface compared to commonly used PICCs, based on platelet count. The AngioDynamics BioFlo PICC is a product of AngioDynamics (Latham, NY, USA), and has been approved by the US Food and Drug Administration (FDA).

“BioFlo technology shows promise in decreasing the accumulation of catheter-related thrombus without incorporation of heparin, antibiotics, antimicrobials or any other transient materials typically associated with coated or impregnated technologies,” said Joseph DeVivo, president and CEO of AngioDynamics. “BioFlo technology provides AngioDynamics with a truly disruptive technology which we believe will drive increased demand for our vascular access products.”

As an additive, Endexo has significant manufacturing advantages over other antithrombogenic coating or impregnation alternatives, and does not change the mechanical design parameters or functional properties of the underlying medical device. By enhancing the biocompatibility of medical devices, Endexo may ultimately improve their safety and effectiveness and advance the quality of care provided to patients.

Related Links:
AngioDynamics


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.